Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 13, 2014 2:30pm
160 Views
Post# 22319202

RE:RE:RE:KD and Phase 3

RE:RE:RE:KD and Phase 3Hi fouremm. Excellent perspective. I haven't been involved in the dialogue until recently but your perspective is the conclusion I've been moving toward.

It is very frustrating that a delay in the Zenith IPO traces to Don doing an RVX deal. If his reputation and capabilities are really an issue the board should be looking for a replacement. If he pulls off a great deal I'll gladly eat crow.

On the issue of dilution why does anyone care as long as all investors are treated equally and that it drives the business forward. I'd rather have a diluted $10 share than a protected $.70 share with no hope of growth.

It seems to me that the KD opportunity is huge. It is a guarantee that this can keep moving forward and a huge vote of confidence. If it is true then it does provide negotiating leverage. So then the key is "who should be doing the negotiating?".

Thanks for the excellent perspective.
Toinv


Bullboard Posts